H.C. Wainwright has recently reduced Cassava Sciences Inc (SAVA) stock to Neutral rating, as announced on November 26, 2024, according to Finviz. Earlier, on October 8, 2024, H.C. Wainwright had ...

H.C. Wainwright raised the firm’s price target on Akero Therapeutics (AKRO) to $72 from $50 and keeps a Buy rating on the shares after the ...

Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.61 which represents a slight increase of $0.02 or 0.44% from the prior close of $4.59. The stock opened at $4.59 and touched a low ...

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Hold rating on Agenus (AGEN – Research Report). The company’s shares ...

The confidence in Voyager Therapeutics (NASDAQ:VYGR)' stock is further supported by the company's strategic collaborations, ...

In conclusion, H.C. Wainwright's analyst remains optimistic about Immunocore's prospects, underpinned by the potential of its diverse pipeline and upcoming clinical milestones. With a market ...

Analysts at HC Wainwright issued their FY2024 EPS estimates for Exodus Movement in a report issued on Thursday, January 23rd. HC Wainwright analyst K. Dede forecasts that the company will post ...

Nuvation Bio (NYSE:NUVB – Free Report) had its price objective upped by HC Wainwright from $10.00 to $11.00 in a research ...

H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...

H.C. Wainwright raised the firm’s price target on Sana Biotechnology (SANA) to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% ...